Abstract
Sequential combination of immunogenic cell death (ICD)-induced interventions with subsequent immunotherapy has shown efficacy in preclinical models and clinical evaluation. Recently, a clinical trial enrolling small cell lung cancer patients treated with amrubicin together with PD-1 blockade confirmed the notion that ICD sensitizes tumors to immune checkpoint inhibitors.
Original language | English |
---|---|
Article number | 1996686 |
Journal | OncoImmunology |
Volume | 10 |
Issue number | 1 |
DOIs | |
Publication status | Published - 1 Jan 2021 |
Keywords
- Immunotherapy
- anthracycline
- lung cancer